 The purpose of this study is to determine if an imaging test called computed tomography angiography CTA can predict which individuals with ICH will experience significant growth in the size of the hemorrhage. Growth of the hemorrhage can cause additional injury and may worsen the outcome. For individuals who are at high risk for hemorrhage growth based on CTA results i.e., a positive CTA spot sign, evidence of contrast leakage within the hemorrhage, the study will compare the effects of a drug called recombinant activated factor VII NovoSeven or rFVIIa with a placebo to determine which is better for reducing ICH growth. 